Finally, we propose the drug resistance coordination model that elucidates the rationale for P-gp inhibition as a treatment approach for cancer patients, highlighting that co-inhibition of P-gp and non-P-gp-mediated drug resistance may be required for overcoming MDR in refractory cancer patients. This evidence concerns the gene PGP and cancer.